GLP-1 receptor agonists are best known as medicines for type 2 diabetes and weight loss. Drugs like semaglutide, liraglutide, and exenatide have become widely used for blood sugar control and obesity. But new research suggests they may also help protect joints and bones.
A recent review explores how GLP-1 receptor agonists might reduce inflammation in osteoarthritis (OA) and improve bone strength in osteoporosis (OP). These two conditions are common in older adults and often occur together. If one class of drugs could help both, it would be an important breakthrough.
Why Osteoarthritis and Osteoporosis Matter
Osteoarthritis is a joint disease caused by cartilage breakdown, inflammation, and changes in the bone under the joint. It leads to pain, stiffness, and loss of movement. By 2020, about 596 million people worldwide were living with OA.
Osteoporosis is a disease that weakens bones. It lowers bone mineral density and makes bones more likely to break. Globally, about 18% of people are affected, with higher rates in women.
These two conditions often happen in middle-aged and older adults. They reduce quality of life and increase disability. Right now, there are no medications that effectively treat both diseases at the same time. That is why researchers are exploring new options.
How GLP-1 Drugs May Help in Osteoarthritis
GLP-1 receptor agonists (GLP-1RAs) work by activating the GLP-1 receptor. These receptors are found not only in the pancreas but also in cartilage and joint tissue.
1. Reducing Inflammation
Osteoarthritis involves low-grade, ongoing inflammation inside the joint. Studies in animal models show that GLP-1RAs:
- Lower inflammatory chemicals like TNF-α, IL-1β, and IL-6
- Reduce harmful signaling pathways linked to inflammation
- Shift immune cells (macrophages) from a pro-inflammatory state to an anti-inflammatory state
By calming inflammation, GLP-1 drugs may slow joint damage.
2. Protecting Cartilage
Cartilage contains important proteins like collagen type II and aggrecan. In OA, enzymes break these down.
Research shows GLP-1RAs:
- Lower the activity of cartilage-breaking enzymes (such as MMPs and ADAMTS)
- Increase production of collagen and aggrecan
- Reduce oxidative stress inside cartilage cells
In animal studies, liraglutide significantly reduced cartilage damage scores after several weeks of treatment.
3. Effects on Joint Pain
Pain is the main symptom of osteoarthritis. Some studies suggest GLP-1RAs may reduce pain.
In certain animal models, liraglutide improved pain behaviors and reduced synovitis (joint lining inflammation). Human studies in people with knee OA and type 2 diabetes showed:
- Lower pain scores
- Reduced need for pain medications
- Fewer knee surgeries
However, results are mixed. Some studies found no improvement in pain. Researchers believe pain relief may partly come from weight loss and improved metabolism rather than a direct pain-blocking effect.
More clinical studies are needed to confirm how much these drugs help joint pain directly.
How GLP-1 Drugs May Strengthen Bone in Osteoporosis
Bone health depends on balance between two cell types:
- Osteoblasts (build bone)
- Osteoclasts (break down bone)
GLP-1 receptors are found on both types of cells.
1. Promoting Bone Formation
Many studies show GLP-1RAs increase markers of bone formation. In animal models, drugs like liraglutide, semaglutide, and exenatide:
- Increase bone mineral density (BMD)
- Improve bone microstructure
- Increase osteoblast activity
- Promote bone strength and stiffness
These drugs activate pathways like Wnt/β-catenin and PI3K/AKT that encourage bone growth.
Some studies also show GLP-1 drugs reduce fat buildup in bone marrow, which may further support healthy bone formation.
2. Reducing Bone Breakdown
GLP-1RAs may also reduce osteoclast activity. Studies show:
- Lower levels of bone resorption markers (like CTX-1)
- Increased OPG/RANKL ratio, which helps suppress bone breakdown
- Reduced number of osteoclasts in animal models
However, results are not completely consistent. Some studies suggest bone density improves mainly because bone formation increases, not because bone breakdown decreases.
3. Effects on Fracture Risk
Fractures are the most serious consequence of osteoporosis.
Some studies and meta-analyses suggest that liraglutide and lixisenatide reduce fracture risk, especially with longer treatment (over 52 weeks). Animal studies show improved fracture healing and stronger bone repair.
But other studies show no change—or even a possible increased risk—with certain drugs like exenatide.
Researchers believe differences may depend on:
- Length of treatment
- Dose
- Weight loss effects
- Risk of falls
- Individual patient differences
The fracture risk data shows that there could be an increase in fractures, or decrease in fractures. Therefore, more long-term human studies are needed before firm conclusions can be made.
What Are the Limitations of This Research?
Most of the evidence comes from:
- Rodent models that are early animal studies that may not relate to humans
- Laboratory studies which may only show what happens at the cell level and does not correlate to what happens in people
- Patients with diabetes who may have a different response compared to people without diabetes. Larger clinical trials are needed to confirm long-term safety and effectiveness in people without diabetes.
Human studies specifically designed to test GLP-1RAs for OA or OP are still lacking or limited.
Why This Research Is Important
GLP-1 receptor agonists are already widely used for diabetes and weight loss. If they also protect joints and bones, they could serve a dual purpose—especially in older adults who often have both metabolic disease and musculoskeletal problems.
Right now, the evidence is promising but still early. The review concludes that GLP-1RAs may:
- Slow osteoarthritis progression
- Improve bone formation
- Possibly reduce fracture risk
But more large human studies are required before they can be recommended specifically for these conditions.
SourceZheng M, Zhao J, Wang Y, Cui Z, Qiao Z, Wu H, Shi C, Wang X. Exploring new therapeutic drugs for osteoarthritis and osteoporosis: Glucagon-like peptide-1 receptor agonists: A review. Medicine (Baltimore). 2025;104(29):e43239.
Accessed by: https://pmc.ncbi.nlm.nih.gov/articles/PMC12282812/
